Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Our Medicines
DOVATO (dolutegravir/lamivudine)
DOVATO is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 1
JULUCA (dolutegravir/rilpivirine)
JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI. 2
TRIUMEQ (dolutegravir/abacavir/lamivudine)
Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 3
Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patient known to carry the HLA-B*5701
allele. 3
TIVICAY (dolutegravir)
Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. 4
VOCABRIA▼ (Cabotegravir) & REKAMBYS▼ (Rilpivirine)
Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. 5
Vocabria▼ Summary of Product Characteristics
Vocabria▼ Patient Information Leaflet
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the ViiV Healthcare group of companies.
